Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Te-Sheng Chang

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Viruses|January 21, 2023
Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver CirrhosisYung-Yu Hsieh, Wei-Ming Chen, Kao-Chi Chang, et al.
Frontiers in Oncology|March 15, 2021
Epigenetic Silencing of STAT3-Targeted miR-193a, by Constitutive Activation of JAK/STAT Signaling, Leads to Tumor Progression Through Overexpression of YWHAZ in Gastric CancerKuo-Liang Wei, Jian-Liang Chou, Yin-Chen Chen, et al.
Oncogene|April 23, 2022
Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblastsYao-Tsung Tsai, Chih-Yi Li, Yen-Hua Huang, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International|March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registryTe-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Viruses|January 21, 2023
Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver CirrhosisYung-Yu Hsieh, Wei-Ming Chen, Kao-Chi Chang, et al.
Frontiers in Oncology|March 15, 2021
Epigenetic Silencing of STAT3-Targeted miR-193a, by Constitutive Activation of JAK/STAT Signaling, Leads to Tumor Progression Through Overexpression of YWHAZ in Gastric CancerKuo-Liang Wei, Jian-Liang Chou, Yin-Chen Chen, et al.
Oncogene|April 23, 2022
Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblastsYao-Tsung Tsai, Chih-Yi Li, Yen-Hua Huang, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International|March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registryTe-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
Pageof 14